PL1904048T3 - Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych - Google Patents
Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnychInfo
- Publication number
- PL1904048T3 PL1904048T3 PL06777795T PL06777795T PL1904048T3 PL 1904048 T3 PL1904048 T3 PL 1904048T3 PL 06777795 T PL06777795 T PL 06777795T PL 06777795 T PL06777795 T PL 06777795T PL 1904048 T3 PL1904048 T3 PL 1904048T3
- Authority
- PL
- Poland
- Prior art keywords
- glepp
- autoimmune
- treatment
- inhibitors
- inflammatory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106547 | 2005-07-15 | ||
| US70636505P | 2005-08-08 | 2005-08-08 | |
| PCT/EP2006/064288 WO2007009959A1 (en) | 2005-07-15 | 2006-07-14 | Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
| EP06777795A EP1904048B1 (en) | 2005-07-15 | 2006-07-14 | Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1904048T3 true PL1904048T3 (pl) | 2012-04-30 |
Family
ID=35423337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06777795T PL1904048T3 (pl) | 2005-07-15 | 2006-07-14 | Inhibitory Glepp-1 w leczeniu zaburzeń autoimmunizacyjnych i/lub zapalnych |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080207722A1 (pl) |
| EP (1) | EP1904048B1 (pl) |
| JP (1) | JP2009501197A (pl) |
| KR (1) | KR20080036084A (pl) |
| CN (1) | CN101282719A (pl) |
| AT (1) | ATE534380T1 (pl) |
| AU (1) | AU2006271682B2 (pl) |
| BR (1) | BRPI0613400A2 (pl) |
| CA (1) | CA2609929A1 (pl) |
| CY (1) | CY1112148T1 (pl) |
| DK (1) | DK1904048T3 (pl) |
| EA (1) | EA200800342A1 (pl) |
| ES (1) | ES2377881T3 (pl) |
| HR (1) | HRP20110875T1 (pl) |
| IL (1) | IL188735A (pl) |
| MX (1) | MX2008000665A (pl) |
| NO (1) | NO20080781L (pl) |
| PL (1) | PL1904048T3 (pl) |
| PT (1) | PT1904048E (pl) |
| RS (1) | RS52116B (pl) |
| SI (1) | SI1904048T1 (pl) |
| UA (1) | UA94049C2 (pl) |
| WO (1) | WO2007009959A1 (pl) |
| ZA (1) | ZA200710497B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564931T3 (es) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| CN103561573A (zh) * | 2011-04-26 | 2014-02-05 | 印第安纳大学研究与技术公司 | 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途 |
| BR112018012825A2 (pt) * | 2015-12-22 | 2018-12-04 | Syngenta Participations Ag | derivados de oxadiazol microbiocidas |
| CN107936110B (zh) * | 2017-11-07 | 2021-06-22 | 潍坊医学院 | 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制 |
| EP4132523A4 (en) * | 2020-04-06 | 2024-05-15 | Purdue Research Foundation | Novel n-aryl oxamic acids |
| EP4470534A1 (en) * | 2022-01-27 | 2024-12-04 | Vivozon, Inc. | Pharmaceutical composition for preventing or treating mental disorder |
| CN118239851B (zh) * | 2024-03-20 | 2025-07-25 | 蚌埠医科大学 | 一种ptpro抑制剂的制备方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| EP0727406B1 (de) * | 1995-02-16 | 2001-09-05 | MERCK PATENT GmbH | Vinylenverbindungen und flüssigkristallines Medium |
| AU5347496A (en) * | 1995-04-21 | 1996-11-07 | Daiichi Pharmaceutical Co., Ltd. | Ethynylthiazole derivative |
| FR2762514B1 (fr) * | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| EP1434585A1 (en) | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
| CA2463615C (en) * | 2001-10-30 | 2011-07-26 | Applied Research Systems Ars Holding N.V. | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) |
| JP2003171305A (ja) * | 2001-11-30 | 2003-06-20 | Yunie:Kk | 糖尿病改善治療剤 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | N−アルキルスルフォニル置換アミド誘導体 |
| MXPA04007253A (es) * | 2002-01-29 | 2004-10-29 | Applied Research Systems | Derivados de metilenamidas sustituidos como moduladores de proteina tirosina fosfatasas (ptp). |
| JP2006523196A (ja) | 2003-03-11 | 2006-10-12 | ニューロサーチ、アクティーゼルスカブ | 新規kcnqチャネルを調節する化合物及びその医薬用途 |
| JP5198768B2 (ja) * | 2003-07-21 | 2013-05-15 | メルク セローノ ソシエテ アノニム | アルキニルアリールカルボキサミド |
| WO2005007616A1 (en) | 2003-07-23 | 2005-01-27 | Warner-Lambert Company Llc | Diphenylamino ketone derivatives as mek inhibitors |
| BRPI0508790A (pt) * | 2004-04-07 | 2007-09-04 | Applied Research Systems | ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário |
-
2006
- 2006-07-14 PT PT06777795T patent/PT1904048E/pt unknown
- 2006-07-14 BR BRPI0613400-9A patent/BRPI0613400A2/pt not_active IP Right Cessation
- 2006-07-14 UA UAA200800236A patent/UA94049C2/ru unknown
- 2006-07-14 WO PCT/EP2006/064288 patent/WO2007009959A1/en not_active Ceased
- 2006-07-14 CA CA002609929A patent/CA2609929A1/en not_active Abandoned
- 2006-07-14 ES ES06777795T patent/ES2377881T3/es active Active
- 2006-07-14 KR KR1020087003525A patent/KR20080036084A/ko not_active Ceased
- 2006-07-14 DK DK06777795.3T patent/DK1904048T3/da active
- 2006-07-14 JP JP2008520891A patent/JP2009501197A/ja active Pending
- 2006-07-14 MX MX2008000665A patent/MX2008000665A/es active IP Right Grant
- 2006-07-14 US US11/916,097 patent/US20080207722A1/en not_active Abandoned
- 2006-07-14 EP EP06777795A patent/EP1904048B1/en active Active
- 2006-07-14 EA EA200800342A patent/EA200800342A1/ru unknown
- 2006-07-14 ZA ZA200710497A patent/ZA200710497B/xx unknown
- 2006-07-14 SI SI200631196T patent/SI1904048T1/sl unknown
- 2006-07-14 AT AT06777795T patent/ATE534380T1/de active
- 2006-07-14 CN CNA2006800336726A patent/CN101282719A/zh active Pending
- 2006-07-14 RS RS20110580A patent/RS52116B/sr unknown
- 2006-07-14 HR HR20110875T patent/HRP20110875T1/hr unknown
- 2006-07-14 AU AU2006271682A patent/AU2006271682B2/en not_active Expired - Fee Related
- 2006-07-14 PL PL06777795T patent/PL1904048T3/pl unknown
-
2008
- 2008-01-13 IL IL188735A patent/IL188735A/en not_active IP Right Cessation
- 2008-02-13 NO NO20080781A patent/NO20080781L/no not_active Application Discontinuation
-
2011
- 2011-12-14 CY CY20111101240T patent/CY1112148T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006271682B2 (en) | 2012-07-05 |
| CN101282719A (zh) | 2008-10-08 |
| PT1904048E (pt) | 2011-12-19 |
| CY1112148T1 (el) | 2015-11-04 |
| ATE534380T1 (de) | 2011-12-15 |
| EP1904048A1 (en) | 2008-04-02 |
| IL188735A (en) | 2012-07-31 |
| UA94049C2 (ru) | 2011-04-11 |
| EA200800342A1 (ru) | 2008-08-29 |
| NO20080781L (no) | 2008-02-13 |
| US20080207722A1 (en) | 2008-08-28 |
| AU2006271682A1 (en) | 2007-01-25 |
| ZA200710497B (en) | 2009-04-29 |
| ES2377881T3 (es) | 2012-04-02 |
| CA2609929A1 (en) | 2007-01-25 |
| EP1904048B1 (en) | 2011-11-23 |
| JP2009501197A (ja) | 2009-01-15 |
| BRPI0613400A2 (pt) | 2011-01-11 |
| KR20080036084A (ko) | 2008-04-24 |
| RS52116B (sr) | 2012-08-31 |
| HRP20110875T1 (hr) | 2011-12-31 |
| IL188735A0 (en) | 2008-12-29 |
| WO2007009959A1 (en) | 2007-01-25 |
| DK1904048T3 (da) | 2011-12-19 |
| SI1904048T1 (sl) | 2012-01-31 |
| MX2008000665A (es) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| MX338489B (es) | Derivados de hidantoina utiles como inhibidores de kv3. | |
| PL1660507T5 (pl) | Inhibitory proteazomu oraz sposoby ich stosowania | |
| PL2288372T3 (pl) | Mutant IL-2 do zastosowania w leczeniu lub profilaktyce choroby autoimmunizacyjnej | |
| NO20082907L (no) | Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer | |
| NO20083492L (no) | 11-Beta HSD1 inhibitorer | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| EP1885388A4 (en) | TREATMENT AND ASSESSMENT OF INFLAMMATORY DISEASES | |
| JO3358B1 (ar) | معالجات حساسية العيون | |
| MX2010008397A (es) | Inhibidores del receptor de quimioquinas cxcr3. | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| ATE542800T1 (de) | Kinasehemmer und ihre anwendungsverfahren | |
| NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
| DK1651234T3 (da) | Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser | |
| PL3972604T3 (pl) | Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej | |
| EA200900073A1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| NO20076186L (no) | Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav | |
| DE602008005786D1 (de) | C-met-proteinkinasehemmer | |
| NO20080781L (no) | GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer | |
| WO2006057997A3 (en) | Plasmin-inhibitory therapies | |
| MA32474B1 (fr) | Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75 | |
| MX2009005550A (es) | Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. | |
| WO2019115493A3 (en) | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain | |
| EP1909784A4 (en) | CYSTEIN PROTEASE HEMMER OF THE PAPAIN FAMILY FOR THE TREATMENT OF PARASITIC ILLNESSES | |
| MA33555B1 (fr) | Procédés et compositions pour traiter la leucémie |